MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has expanded its artificial intelligence-based intoxication detection platform with the launch of Intox Collect, a new software tool designed to broaden the company's data collection and analytics capabilities across a wider range of substances that affect the central nervous system. The Intox Collect technology enhances the company's ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment, moving beyond alcohol to include multiple central nervous system stimulants and depressants.
The company's AI model currently uses more than 50 million data points, with management expecting that figure to increase further as Intox Collect is deployed. MindBio is developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026. Target industries include mining, aviation, construction, law enforcement, and any environments where intoxication testing is frequently required for safety and compliance.
This expansion represents a significant step in addressing the need for non-invasive, rapid intoxication detection in workplaces and public safety contexts. By incorporating a broader range of substances, the platform could help reduce accidents and improve compliance with safety regulations. The use of AI and machine learning allows for continuous improvement of detection accuracy as more data is collected.
MindBio Therapeutics is a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection. The company's technology aims to provide objective, real-time assessment of impairment, which could replace or supplement traditional methods such as breathalyzers or urine tests. The expansion into detecting stimulants and depressants broadens the potential applications, particularly in industries where impairment from prescription medications or illicit drugs is a concern.
The development of Edge AI kiosk hardware indicates that MindBio is moving toward a product that can be deployed directly at worksites, with local processing to ensure privacy and low latency. The target industries—mining, aviation, construction, law enforcement—are all sectors where impairment can have catastrophic consequences, and where frequent testing is mandated. The prototype testing in Q2 2026 suggests that commercial deployment is still some time away, but the platform's evolution is progressing.
Investors and industry observers will be watching for further data on the platform's accuracy and specificity across different substances. The expansion of the data set to include more than 50 million points provides a robust foundation for the AI models. As the company moves toward hardware deployment, partnerships with enterprises in target industries will be critical for validation and adoption.
For more information about MindBio Therapeutics, visit the company's newsroom at https://ibn.fm/MBQIF.
